Natera Oncology’s Post

📣 A new gastroesophageal cancer trial, DECIPHER, will utilize Natera's personalized and tumor-informed molecular residual disease (MRD) test, Signatera, to guide patient selection and assess the rate of MRD clearance in patients being treated for gastroesophageal cancer. “With an adaptive approach aimed at eliminating MRD, DECIPHER is designed to offer patients a second chance at a cure when they have not responded to standard of care therapies,” said Dr. Elizabeth Smyth, M.D., consultant in medical oncology at Oxford University Hospitals NHS Foundation Trust l and chief investigator of the trial. “Signatera’s personalized, tumor-informed approach, which has demonstrated high sensitivity across several different cancer types including EGC, will be a key component of this study.” Read more in the press release. #Natera #Signatera #CancerResearch https://lnkd.in/gs2Ffgte

📣 A new gastroesophageal cancer trial, DECIPHER, will utilize Natera's personalized and tumor-informed molecular residual disease (MRD) test, Signatera, to guide patient selection and assess the rate of MRD clearance in patients being treated for gastroesophageal cancer. “With an adaptive approach aimed at eliminating MRD, DECIPHER is designed to offer patients a second chance at a cure when they have not responded to standard of care therapies,” said Dr. Elizabeth Smyth, M.D., consultant in medical oncology at Oxford University Hospitals NHS Foundation Trust l and chief investigator of the trial. “Signatera’s personalized, tumor-informed approach, which has demonstrated high sensitivity across several different cancer types including EGC, will be a key component of this study.” Read more in the press release. #Natera #Signatera #CancerResearch https://lnkd.in/gfmExRYc

📣 A new gastroesophageal cancer trial, DECIPHER, will utilize Natera's personalized and tumor-informed molecular residual disease (MRD) test, Signatera, to guide patient selection and assess the rate of MRD clearance in patients being treated for gastroesophageal cancer. “With an adaptive approach aimed at eliminating MRD, DECIPHER is designed to offer patients a second chance at a cure when they have not responded to standard of care therapies,” said Dr. Elizabeth Smyth, M.D., consultant in medical oncology at Oxford University Hospitals NHS Foundation Trust l and chief investigator of the trial. “Signatera’s personalized, tumor-informed approach, which has demonstrated high sensitivity across several different cancer types including EGC, will be a key component of this study.” Read more in the press release. #Natera #Signatera #CancerResearch https://lnkd.in/eAPARqRZ

International Lung Cancer Awareness Day: Meet Our Experts Today, on International Lung Cancer Awareness Day, we recognize the ongoing battle against this disease and emphasize the importance of research, prevention, and advanced treatment. Leading the Lung Oncology Unit at the Sharett Oncology Institute is Professor Hovav Nechushtan, one of Israel's top physicians in his field. Professor Nechushtan has been ranked by Forbes magazine as one of the best doctors in Israel. About a year and a half ago, he was honored as one of the outstanding physicians in the "Medicine with a Soul: @Hadassah Medical Center’s Best Doctors" initiative. Professor Nechushtan: "In personalized medicine for lung cancer, we identify the unique characteristics of each tumor and patient, and tailor a targeted treatment accordingly." We appreciate Professor Nechushtan's contributions to clinical research and personalized medicine in lung cancer. #SharettOncologyInstitute #LungCancerAwarenessDay #FightAgainstCancer #PersonalizedMedicine #TopExperts

Do you know why clinical trials are so important? 💙 They can give access to new treatments, 3 to 5 years earlier if trials are in Australia 💙 They are the only way to change standard medical treatments 💙 They can improve cure rates and chances of surviving 💙 They can improve quality of life during treatment We currently have multiple studies open to recruitment in colorectal cancer, with VADER and RESOLUTE being two of them. Our VADER trial is exploring the effectiveness of a new combination of treatments for metastatic colorectal cancer. The study includes both a clinical trial and a translational research component. The study includes both a clinical trial and a translational research component, and was helped brought to life by community funding. The RESOLUTE clinical trial aims to investigate the value of adding local ablative treatment to standard systemic treatment (chemotherapy), compared to standard treatment only, in people with oligometastatic colorectal cancer. Learn more about our recruiting trials here: gicancer.org.au/OpenTrials #CancerResearch #GICancer

In 2024, an estimated 234,580 new cases of lung cancer will be diagnosed in the US, and sadly, 125,070 people will lose the battle with this devastating disease. With lung cancer remaining one of the most challenging cancers to treat, the need for innovative treatment approaches is more urgent than ever. At Genomate Health, we are committed to transforming these statistics through AI-driven precision oncology. We are proud to share our latest research, published at American Society of Clinical Oncology (ASCO) 2024. Our work focuses on harnessing the power of AI and comprehensive molecular profiling to provide personalized treatment options for lung cancer patients, ultimately enhancing treatment efficacy. Read our full abstract here and discover how Genomate® is paving the way for more precise, effective lung cancer treatments: https://lnkd.in/gXhg-8mD #LungCancerAwareness #PrecisionOncology #AI #CancerTreatment 👏 Anna Dirner, Robert Doczi, PhD, Dora Kormos, Dóra Lakatos, Márton Bolyácz, Dóra Tihanyi, Akos Takacs, Ákos Boldizsár PhD, Mária Kocsis-Steinbach, Barbara Vodicska PhD, Réka Szalkai-Dénes, Edit Varkondi, Julia Deri, Dora Mathiasz, Istvan Valyi-Nagy, Richard SCHWAB M.D., Maud Kamal,PhD, Christophe Le Tourneau, Urban laszlo, Istvan Petak, MD, PhD

The global oncology community gathered at ASCO 2024 from May 31st to June 4th, 2024. The theme of the meeting was The Art and Science of Cancer Care: From Comfort to Cure. Oncology professionals from across the globe were united and forged collaborations to change the landscape of cancer care. Our team at THB brings to you the important highlights of Breast Cancer- Key Findings on Approved Therapies. >> Eribulin could be considered a viable alternative treatment option to taxane-based therapies. >> T-DXd has demonstrated promising efficacy in HER2 low and HER2 ultra-low advanced breast cancer patients who have previously been treated with endocrine therapy >> Abemaciclib + Fulvestrant shows promising clinical efficacy in CDKi Pretreated HER2-Advanced Breast Cancer These findings presented at the conference highlight the crucial need for ongoing research and advancements. They also offer significant treatment options and a ray of hope for Indian patients who require medical attention. Author- Arun Nayak | Reviewer- Lavina Yadav #ASCO2024 #BreastCancer #ClinicalTrials #OncologyInnovations

Promising findings in ASCO 2024 These results have the potential to alter current breast cancer treatment patterns in real-world practice. #ASCO2024

MITAZALIMAB DOUBLES THE 18-MONTHS SURVIVAL RATE IN mPDAC. Earlier this week Alligator Bioscience AB released updated results from the phase 2 study with mitazalimab in first line metastatic pancreatic cancer. At the 18 months follow-up overall survival had increased to 14.9 months and the unprecedented durability of response to 12.6 months. Mitazalimab continued to drive tumor immunity, manifest by deepening of tumor responses and identification of late objective responders. Longest ongoing treatment duration was 24 months. Importantly, mitazalimab almost doubles the likelihood of being alive at the 18-month timepoint compared to data published for standard of care chemotherapy alone. We are immensely proud and encouraged by these data, and we are committed to bring mitazalimab to patients with metastatic pancreatic cancer as fast as possible. You can find the press release here https://lnkd.in/dS5pppC8 And the Lancet Oncology paper on the topline data here https://lnkd.in/dRt8iqDp #mitazalimab #phase2 #pancreaticcancer #pdac #oncology #cancer #immunooncology #IO #alligator #atorx #immunetherapy #cancerresearch #cd40 #lancet

sNDA Submitted for New Liver Cancer Treatment—The NMPA has accepted our sNDA for toripalimab combined with bevacizumab as a first-line treatment for hepatocellular carcinoma (HCC)! Liver cancer remains a considerable challenge worldwide, and the majority of cases are diagnosed at an advanced stage. In 2022, China reported 368,000 new cases (42.4% of global cases) and 317,000 deaths (41.7% of global cases) due to liver cancer. The HEPATORCH study evaluating toripalimab plus bevacizumab versus sorafenib for HCC demonstrated significant survival benefits. Having been approved for 10 indications, toripalimab has again showcased its versatility and efficacy in tackling cancer, and this new sNDA approval will greatly benefit HCC patients. Learn more: https://lnkd.in/eUcc5rib #toripalimab #livercancer #hepatocellularcarcinoma #cancertreatment #medicalinnovation #oncology #healthcare #topalliance #junshibiosciences